{"id":48842,"date":"2022-09-27T08:02:15","date_gmt":"2022-09-27T06:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rd-day-presentations-to-highlight-transgenes-competitive-positioning-capabilities-to-engineer-novel-immunotherapies-for-patients-with-cancer-and-update-on-initial-clinical-data\/"},"modified":"2022-09-27T08:02:15","modified_gmt":"2022-09-27T06:02:15","slug":"rd-day-presentations-to-highlight-transgenes-competitive-positioning-capabilities-to-engineer-novel-immunotherapies-for-patients-with-cancer-and-update-on-initial-clinical-data","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rd-day-presentations-to-highlight-transgenes-competitive-positioning-capabilities-to-engineer-novel-immunotherapies-for-patients-with-cancer-and-update-on-initial-clinical-data\/","title":{"rendered":"R&D Day: Presentations to Highlight Transgene\u2019s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data"},"content":{"rendered":"
\n

\nMeeting to highlight Company\u2019s innovative portfolio, supported by updated clinical data, demonstrating the potential of therapeutic vaccine and oncolytic virus candidates to improve cancer patient outcomes\n<\/p>\n

<\/a><\/p>\n

STRASBOURG, France–(BUSINESS WIRE)–#HBV<\/a>–Regulatory News:\n<\/p>\n

\nTransgene (Euronext Paris: TNG) (Paris:TNG), <\/b>a biotech company that designs and develops virus-based immunotherapeutics against cancer, will host today an R&D event for investors and research analysts in Paris.\n<\/p>\n

\nHedi Ben Brahim, CEO of Transgene<\/b>, commenting on the Company\u2019s R&D Day said: \u201cToday\u2019s event will highlight our world leading scientific and translational expertise which has allowed us to design the next generation of virus-based immunotherapies against cancer. We will provide updated data on the previous Phase Ib\/II trial of TG4001 and avelumab in HPV16-positive cancer patients and the updated clinical follow up of patients enrolled in the two Phase I trials with TG4050, which are all positive and consistent with previous findings. In addition, we will outline the progress we have made with our exciting Invir.IO\u2122 platform, which via intravenous administration could significantly broaden the potential of oncolytic viral therapies. I would like to thank our expert speakers for participating in our R&D event which I am confident will demonstrate that Transgene remains on track to deliver a number of important value adding clinical milestones over the next 18 months.\u201d<\/i>\n<\/p>\n

\nThe event, which features presentations by leading clinicians and scientists from around the world, as well as key members of the Transgene management team, provides insights on:\n<\/p>\n

\n– TG4001<\/b>, with updated data from the previous trial (Phase Ib\/II) evaluating the combination of TG4001 and avelumab in HPV16-positive cancers;
\n
– TG4050<\/b>, with updated follow up data from the two Phase I trials in ovarian cancer and head and neck cancer;
\n
– The progress of the Invir.IO\u2122 platform<\/b>, with a focus on a novel oncolytic virus vectorizing human IL-12 that has been designed to be administered intravenously.\n<\/p>\n

\nThe R&D Day\u2019s key speakers, which also includes key members of Transgene\u2019s management team, are:<\/b>\n<\/p>\n